139 related articles for article (PubMed ID: 8942490)
41. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
42. Trial of routine gonadotropin releasing hormone agonist treatment before abdominal hysterectomy for leiomyoma.
Balasch J; Manau D; Mimó J; Duran M; Puerto B; Vanrell JA
Acta Obstet Gynecol Scand; 1995 Aug; 74(7):562-5. PubMed ID: 7618457
[TBL] [Abstract][Full Text] [Related]
43. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR
Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352
[TBL] [Abstract][Full Text] [Related]
45. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
Mizutani T; Sugihara A; Nakamuro K; Terada N
J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
[TBL] [Abstract][Full Text] [Related]
46. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
Liang Y; Wei H; Zhang JL; Hou L; Luo XP
Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
[TBL] [Abstract][Full Text] [Related]
47. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
48. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
Rolland R; Franssen AM; Willemsen WN; Corbey RS
Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
[No Abstract] [Full Text] [Related]
49. Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas.
Uemura T; Mori J; Yoshimura Y; Minaguchi H
Asia Oceania J Obstet Gynaecol; 1991 Dec; 17(4):315-20. PubMed ID: 1724899
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of low dose of gonadotropin releasing hormone agonist on hormonal flare-up.
Bständig B; Cédrin-Durnerin I; Hugues JN
J Assist Reprod Genet; 2000 Feb; 17(2):113-7. PubMed ID: 10806591
[TBL] [Abstract][Full Text] [Related]
51. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure.
Bozzini N; Rodrigues CJ; Petti DA; Bevilacqua RG; Gonçalves SP; Pinotti JA
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):330-4. PubMed ID: 12716317
[TBL] [Abstract][Full Text] [Related]
52. Unsuspected uterine leiomyosarcoma discovered during treatment with a gonadotropin-releasing hormone analogue: a case report and literature review.
Milman D; Zalel Y; Biran H; Open M; Caspi B; Hagay Z; Dgani R
Eur J Obstet Gynecol Reprod Biol; 1998 Feb; 76(2):237-40. PubMed ID: 9481582
[TBL] [Abstract][Full Text] [Related]
53. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings.
Wang PH; Yang AH; Yuan CC; Lee WL; Chao HT
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Nov; 61(11):625-9. PubMed ID: 9872018
[TBL] [Abstract][Full Text] [Related]
54. Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience.
Okuda S; Oshio K; Shinmoto H; Tanimoto A; Asada H; Fujii T; Yoshimura Y; Kuribayashi S
Radiology; 2008 Sep; 248(3):917-24. PubMed ID: 18710984
[TBL] [Abstract][Full Text] [Related]
55. The application of GnRH analogues in the treatment of uterine myomas in perimenopausal women.
Dragojević-Dikić S; Vućić M
Ginekol Pol; 1998 Jan; 69(1):28-33. PubMed ID: 9553319
[TBL] [Abstract][Full Text] [Related]
56. Long-term use of an LH-RH agonist in the management of uterine leiomyomas: a study of 17 cases.
George M; Lhomme C; Lefort J; Gras C; Comaru-Schally AM; Schally AV
Int J Fertil; 1989; 34(1):19-24. PubMed ID: 2565299
[TBL] [Abstract][Full Text] [Related]
57. A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue.
Filicori M; Hall DA; Loughlin JS; Rivier J; Vale W; Crowley WF
Am J Obstet Gynecol; 1983 Nov; 147(6):726-7. PubMed ID: 6356927
[No Abstract] [Full Text] [Related]
58. Triptorelin to prevent hysterectomy in patients with leiomyomas.
van Leusden HA
Lancet; 1988 Aug; 2(8609):508. PubMed ID: 2900426
[No Abstract] [Full Text] [Related]
59. Prolapsed leiomyoma with severe haemorrhage after GnRH analogue therapy.
Kriplani A; Agarwal N; Parul D; Bhatla N; Saxena AK
J Obstet Gynaecol; 2002 Jul; 22(4):449-51. PubMed ID: 12521484
[No Abstract] [Full Text] [Related]
60. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
Maheux R; Lemay A; Turcot-Lemay L
Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
